NFκB inhibition reduced HG- and CML-mediated induction of CD147 mRNA and protein levels by 59–72% and 56–74%, respectively (Figure 3A,B). The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.